364 related articles for article (PubMed ID: 27286189)
61. ROS triggered cleavage of thioketal moiety to dissociate prodrug nanoparticles for chemotherapy.
Pan Q; Deng X; Gao W; Chang J; Pu Y; He B
Colloids Surf B Biointerfaces; 2020 Oct; 194():111223. PubMed ID: 32615519
[TBL] [Abstract][Full Text] [Related]
62. The effect of linkers on the self-assembling and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles.
Wang Y; Wang X; Deng F; Zheng N; Liang Y; Zhang H; He B; Dai W; Wang X; Zhang Q
J Control Release; 2018 Jun; 279():136-146. PubMed ID: 29655991
[TBL] [Abstract][Full Text] [Related]
63. Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.
Devalapally H; Rajan KS; Akkinepally RR; Devarakonda RK
Drug Dev Ind Pharm; 2008 Aug; 34(8):789-95. PubMed ID: 18608462
[TBL] [Abstract][Full Text] [Related]
64. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
[TBL] [Abstract][Full Text] [Related]
65. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
66. Effect of intratumoral injection on the biodistribution and therapeutic potential of novel chemophor EL-modified single-walled nanotube loading doxorubicin.
Liu H; Xu H; Wang Y; He Z; Li S
Drug Dev Ind Pharm; 2012 Sep; 38(9):1031-8. PubMed ID: 22794192
[TBL] [Abstract][Full Text] [Related]
67. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.
Garg M; Madan J; Pandey RS; Sardana S; Katyal A; Chandra R
Anticancer Drugs; 2012 Sep; 23(8):836-45. PubMed ID: 22407250
[TBL] [Abstract][Full Text] [Related]
68. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
69. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
Siegal T; Horowitz A; Gabizon A
J Neurosurg; 1995 Dec; 83(6):1029-37. PubMed ID: 7490617
[TBL] [Abstract][Full Text] [Related]
70. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
71. In vitro evaluation of doxorubicin-incorporated magnetic albumin nanospheres.
Zeybek A; Şanlı-Mohamed G; Ak G; Yılmaz H; Şanlıer ŞH
Chem Biol Drug Des; 2014 Jul; 84(1):108-15. PubMed ID: 24524300
[TBL] [Abstract][Full Text] [Related]
72. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer.
Maeng JH; Lee DH; Jung KH; Bae YH; Park IS; Jeong S; Jeon YS; Shim CK; Kim W; Kim J; Lee J; Lee YM; Kim JH; Kim WH; Hong SS
Biomaterials; 2010 Jun; 31(18):4995-5006. PubMed ID: 20347138
[TBL] [Abstract][Full Text] [Related]
73. Core-shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer.
Shen S; Wu L; Liu J; Xie M; Shen H; Qi X; Yan Y; Ge Y; Jin Y
Int J Pharm; 2015; 486(1-2):380-8. PubMed ID: 25841570
[TBL] [Abstract][Full Text] [Related]
74. A tumor-targeting near-infrared laser-triggered drug delivery system based on GO@Ag nanoparticles for chemo-photothermal therapy and X-ray imaging.
Shi J; Wang L; Zhang J; Ma R; Gao J; Liu Y; Zhang C; Zhang Z
Biomaterials; 2014 Jul; 35(22):5847-61. PubMed ID: 24746963
[TBL] [Abstract][Full Text] [Related]
75. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
76. Radiotherapy-assisted tumor selective metronomic oral chemotherapy.
Chung SW; Kweon S; Lee BS; Kim GC; Mahmud F; Lee H; Cho YS; Choi JU; Jeon OC; Kim JW; Kim SW; Kim IS; Kim SY; Byun Y
Int J Cancer; 2017 Nov; 141(9):1912-1920. PubMed ID: 28635011
[TBL] [Abstract][Full Text] [Related]
77. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
[TBL] [Abstract][Full Text] [Related]
78. Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model.
Lin J; Shigdar S; Fang DZ; Xiang D; Wei MQ; Danks A; Kong L; Li L; Qiao L; Duan W
PLoS One; 2014; 9(7):e103736. PubMed ID: 25072631
[TBL] [Abstract][Full Text] [Related]
79. Cucumber mosaic virus as drug delivery vehicle for doxorubicin.
Zeng Q; Wen H; Wen Q; Chen X; Wang Y; Xuan W; Liang J; Wan S
Biomaterials; 2013 Jun; 34(19):4632-42. PubMed ID: 23528229
[TBL] [Abstract][Full Text] [Related]
80. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect.
Son YJ; Jang JS; Cho YW; Chung H; Park RW; Kwon IC; Kim IS; Park JY; Seo SB; Park CR; Jeong SY
J Control Release; 2003 Aug; 91(1-2):135-45. PubMed ID: 12932645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
